67 related articles for article (PubMed ID: 16707926)
21. Heparin-mediated conformational changes in fibronectin expose vascular endothelial growth factor binding sites.
Mitsi M; Hong Z; Costello CE; Nugent MA
Biochemistry; 2006 Aug; 45(34):10319-28. PubMed ID: 16922507
[TBL] [Abstract][Full Text] [Related]
22. IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain.
Booth BA; Boes M; Andress DL; Dake BL; Kiefer MC; Maack C; Linhardt RJ; Bar K; Caldwell EE; Weiler J
Growth Regul; 1995 Mar; 5(1):1-17. PubMed ID: 7538367
[TBL] [Abstract][Full Text] [Related]
23. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
24. Heparan sulfate proteoglycans mediate the angiogenic activity of the vascular endothelial growth factor receptor-2 agonist gremlin.
Chiodelli P; Mitola S; Ravelli C; Oreste P; Rusnati M; Presta M
Arterioscler Thromb Vasc Biol; 2011 Dec; 31(12):e116-27. PubMed ID: 21921258
[TBL] [Abstract][Full Text] [Related]
25. Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cells.
Deissler HL; Rehak M; Busch C; Wolf A
Exp Eye Res; 2022 Mar; 216():108945. PubMed ID: 35038456
[TBL] [Abstract][Full Text] [Related]
26. Disulfide structure of the heparin binding domain in vascular endothelial growth factor: characterization of posttranslational modifications in VEGF.
Keck RG; Berleau L; Harris R; Keyt BA
Arch Biochem Biophys; 1997 Aug; 344(1):103-13. PubMed ID: 9244387
[TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity.
Kawamura H; Li X; Harper SJ; Bates DO; Claesson-Welsh L
Cancer Res; 2008 Jun; 68(12):4683-92. PubMed ID: 18559514
[TBL] [Abstract][Full Text] [Related]
28. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
29. Production of soluble human vascular endothelial growth factor VEGF-A165-heparin binding domain in Escherichia coli.
Seyedarabi A; Cheng L; Zachary I; Djordjevic S
PLoS One; 2013; 8(2):e55690. PubMed ID: 23409021
[TBL] [Abstract][Full Text] [Related]
30. Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization.
Dougher M; Terman BI
Oncogene; 1999 Feb; 18(8):1619-27. PubMed ID: 10102632
[TBL] [Abstract][Full Text] [Related]
31. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization.
Olsson AK; Johansson I; Akerud H; Einarsson B; Christofferson R; Sasaki T; Timpl R; Claesson-Welsh L
Cancer Res; 2004 Dec; 64(24):9012-7. PubMed ID: 15604266
[TBL] [Abstract][Full Text] [Related]
32. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
[TBL] [Abstract][Full Text] [Related]
33. Solution structure of the VEGF-binding domain of Flt-1: comparison of its free and bound states.
Starovasnik MA; Christinger HW; Wiesmann C; Champe MA; de Vos AM; Skelton NJ
J Mol Biol; 1999 Oct; 293(3):531-44. PubMed ID: 10543948
[TBL] [Abstract][Full Text] [Related]
34. The VD1 neutralizing antibody to vascular endothelial growth factor-D: binding epitope and relationship to receptor binding.
Davydova N; Roufail S; Streltsov VA; Stacker SA; Achen MG
J Mol Biol; 2011 Apr; 407(4):581-93. PubMed ID: 21315726
[TBL] [Abstract][Full Text] [Related]
35. Chimeric VEGF-E(NZ7)/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation.
Zheng Y; Murakami M; Takahashi H; Yamauchi M; Kiba A; Yamaguchi S; Yabana N; Alitalo K; Shibuya M
Arterioscler Thromb Vasc Biol; 2006 Sep; 26(9):2019-26. PubMed ID: 16794222
[TBL] [Abstract][Full Text] [Related]
36. Localization of vascular response to VEGF is not dependent on heparin binding.
Springer ML; Banfi A; Ye J; von Degenfeld G; Kraft PE; Saini SA; Kapasi NK; Blau HM
FASEB J; 2007 Jul; 21(9):2074-85. PubMed ID: 17325231
[TBL] [Abstract][Full Text] [Related]
37. [Snake venom proteins related to "vascular endothelial growth factor": new tools for therapeutic angiogenesis].
Aloui Z; Essafi-Benkhadir K; Karoui H; Gasmi A
Arch Inst Pasteur Tunis; 2013; 90(1-4):23-37. PubMed ID: 26012208
[TBL] [Abstract][Full Text] [Related]
38. Snake venom vascular endothelial growth factors (svVEGFs): Unravelling their molecular structure, functions, and research potential.
Ferreira IG; Pucca MB; Oliveira IS; Cerni FA; Jacob BCDS; Arantes EC
Cytokine Growth Factor Rev; 2021 Aug; 60():133-143. PubMed ID: 34090786
[TBL] [Abstract][Full Text] [Related]
39. Molecular and functional diversity of vascular endothelial growth factors.
Yamazaki Y; Morita T
Mol Divers; 2006 Nov; 10(4):515-27. PubMed ID: 16972015
[TBL] [Abstract][Full Text] [Related]
40. Multiple mechanisms for exogenous heparin modulation of vascular endothelial growth factor activity.
Wijelath E; Namekata M; Murray J; Furuyashiki M; Zhang S; Coan D; Wakao M; Harris RB; Suda Y; Wang L; Sobel M
J Cell Biochem; 2010 Oct; 111(2):461-8. PubMed ID: 20524207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
